Zhai Zhenyu, Zou Pengtao, Liu Fuxiang, Xia Zirong, Li Juxiang
Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Front Cell Dev Biol. 2021 Apr 1;9:649045. doi: 10.3389/fcell.2021.649045. eCollection 2021.
Cardiomyocyte death is a fundamental progress in cardiomyopathy. However, the mechanism of triggering the death of myocardial cells remains unclear. Ferroptosis, which is the nonapoptotic, iron-dependent, and peroxidation-driven programmed cell death pathway, that is abundant and readily accessible, was not discovered until recently with a pharmacological approach. New researches have demonstrated the close relationship between ferroptosis and the development of many cardiovascular diseases, and several ferroptosis inhibitors, iron chelators, and small antioxidant molecules can relieve myocardial injury by blocking the ferroptosis pathways. Notably, ferroptosis is gradually being considered as an important cell death mechanism in the animal models with multiple cardiomyopathies. In this review, we will discuss the mechanism of ferroptosis and the important role of ferroptosis in cardiomyopathy with a special emphasis on the value of ferroptosis as a potential novel diagnostic and therapeutic target for patients suffering from cardiomyopathy in the future.
心肌细胞死亡是心肌病发展的一个基本过程。然而,触发心肌细胞死亡的机制仍不清楚。铁死亡是一种非凋亡性、铁依赖性和过氧化驱动的程序性细胞死亡途径,这种途径丰富且易于研究,直到最近才通过药理学方法被发现。新的研究表明铁死亡与许多心血管疾病的发展密切相关,几种铁死亡抑制剂、铁螯合剂和小分子抗氧化剂可以通过阻断铁死亡途径来减轻心肌损伤。值得注意的是,在多种心肌病动物模型中,铁死亡正逐渐被视为一种重要的细胞死亡机制。在这篇综述中,我们将讨论铁死亡的机制以及铁死亡在心肌病中的重要作用,特别强调铁死亡作为未来心肌病患者潜在新型诊断和治疗靶点的价值。